LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
MNOV
MediciNova, Inc.
There isn't enough reported data to score MNOV yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MNOV Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
MNOV's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MNOV PE Valuation
MNOV has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MNOV Forward outlook
There aren't enough analyst estimates for MNOV to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MNOV on earnings quality, reporting a profit while its opponent remains loss making.
MNOV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.21 | +$0.04 |
| Q2 2026 | -$0.21 | +$0.04 |
| Q1 2026 | -$0.23 | $0.00 |
| Q4 2025 | -$0.24 | -$0.01 |
| Q3 2025 | -$0.25 | -$0.04 |
| Q2 2025 | -$0.25 | -$0.09 |
| Q1 2025 | -$0.23 | -$0.06 |
| Q4 2024 | -$0.23 | -$0.06 |
MNOV is still losing money, but less than at its worst: $0.21 per share over the past year, against $0.31 at its worst in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MNOV in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MNOV on profitability, with a higher operating margin.
MNOV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $138.6K | +12% |
| Q2 2026 | $458.4K | +241% |
MNOV's revenue is recovering but still below its 2021 peak: $138,555 last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2209% | +533 points |
| Q2 2026 | -554% | +2126 points |
| Q1 2026 | -1517% | N/A |
| Q4 2025 | -2038% | N/A |
| Q3 2025 | -2742% | N/A |
| Q2 2025 | -2680% | N/A |
| Q3 2023 | -115% | N/A |
| Q3 2021 | -9605% | N/A |
MNOV's operating margin was −2209% last quarter, up 533 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
MNOV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.5M | +$302.6K |
| Q4 2025 | -$2M | -$85.1K |
| Q1 2025 | -$3.8M | +$84.6K |
| Q4 2024 | -$1.9M | -$1.4M |
| Q3 2024 | -$2M | -$657.8K |
| Q1 2024 | -$3.9M | -$690.8K |
| Q1 2023 | -$3.2M | +$551K |
| Q4 2021 | -$3.6M | -$1.7M |
MNOV has burned cash in almost every quarter: −$10M over the past year, against −$12M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MNOV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MNOV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +157K shares |
| 1 year | +0.7% | +332K shares |
| 3 years | +0.7% | +332K shares |
| 5 years | +0.8% | +390K shares |
| Available history | +14% | +6.2M shares |
MNOV has 49M diluted shares, up 0.7% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MNOV Net Leverage
MNOV's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MNOV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.6 | Neutral |
| Stochastic | 4.9 | Oversold |
MNOV's weekly RSI is 47 (neutral) and its Stochastic is 5 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MNOV PE vs Healthcare Sector
MNOV has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MNOV on trend strength, trading above more of its moving averages.
MNOV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.62 | 14% below |
| 20 week MA | $1.60 | 13% below |
| 50 week MA | $1.51 | 7.3% below |
| 100 week MA | $1.50 | 6.7% below |
| 200 week MA | $1.67 | 16% below |
MNOV is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MNOV on returns for 2026, with the stronger performance.
MNOV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.50 | $5.63 | -13% |
| 2021 | $5.63 | $2.79 | -50% |
| 2022 | $2.79 | $2.00 | -28% |
| 2023 | $2.00 | $1.50 | -25% |
| 2024 | $1.50 | $2.07 | +38% |
| 2025 | $2.07 | $1.27 | -39% |
| 2026 YTD | $1.27 | $1.40 | +10% |
MNOV has finished lower in five of the last six years. It's up 10% so far in 2026.